 | |
| Clinical data | |
|---|---|
| Other names | ANEB-001; ANEB001; V-24343; V24343 |
| Drug class | Cannabinoid receptor antagonist;CannabinoidCB1 receptorantagonist;Cannabinoid antidote |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H24ClF3N2O2 |
| Molar mass | 440.89 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Selonabant (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name; developmental code namesANEB-001,V-24343) is acannabinoidCB1 receptorantagonist which is under development for the treatment of acutecannabinoidintoxication.[1][2][3] It was also previously being developed to treatobesity, but development for this indication was discontinued.[1] The drug is administered byintravenous infusion.[1] It dramatically reduced the subjective effects ofΔ9-tetrahydrocannabinol (THC) in aclinical trial.[3] Selonabant is being developed by Vernalis and Anebulo Pharmaceuticals.[1][2] As of December 2024, it is inphase 2 trials.[1][2]
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it. |